Cargando…

Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study

BACKGROUND: COVID-19 is a respiratory illness caused by SARS-CoV-2. Pharmaceutical companies aim to control virus spread through effective drugs. This study investigates chromone compound derivatives’ ability to inhibit viral entry and prevent replication. METHOD: This study investigated the inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakibay Senobari, Zahra, Masoumian Hosseini, Mohsen, Teimouri, Mohammad Bagher, Rezayan, Ali Hossein, Samarghandian, Saeed, Hekmat, Azadeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515067/
https://www.ncbi.nlm.nih.gov/pubmed/37735703
http://dx.doi.org/10.1186/s13104-023-06508-7
_version_ 1785108867346071552
author Shakibay Senobari, Zahra
Masoumian Hosseini, Mohsen
Teimouri, Mohammad Bagher
Rezayan, Ali Hossein
Samarghandian, Saeed
Hekmat, Azadeh
author_facet Shakibay Senobari, Zahra
Masoumian Hosseini, Mohsen
Teimouri, Mohammad Bagher
Rezayan, Ali Hossein
Samarghandian, Saeed
Hekmat, Azadeh
author_sort Shakibay Senobari, Zahra
collection PubMed
description BACKGROUND: COVID-19 is a respiratory illness caused by SARS-CoV-2. Pharmaceutical companies aim to control virus spread through effective drugs. This study investigates chromone compound derivatives’ ability to inhibit viral entry and prevent replication. METHOD: This study investigated the inhibitory effect of chromone-embedded peptidomimetics and furopyrimidines on 7BZ5 from Severe Acute Respiratory Syndrome CoV-2, Homo sapiens, and 6LU7 from Bat SARS-like CoV using molecular docking. The crystal structure of these proteins was obtained from the Protein Data Bank, and the inhibition site was determined using ligand binding interaction options. The 3D structure was protonated and energetically minimised using MOE software. Chromone derivatives were designed in three dimensions, and their energy was minimised using MOE 2019. The molecular drug-likeness was calculated using SwissADME, Lipinski and Benigni-Bossa’s rule, and toxicity was calculated using Toxtree v3.1.0 software. Compounds with pharmacological properties were selected for molecular docking, and interactions were assessed using MOE 2019. MD simulations of Mpro-ch-p complexes were performed to evaluate root mean square fluctuations (RMSF) and measure protein stability. RESULT: The pharmacokinetic tests revealed that chromone derivatives of the peptidomimetic family have acceptable pharmacokinetic activity in the human body. Some compounds, such as Ch-p1, Ch-p2, Ch-p6, Ch-p7, Ch-p12, and Ch-p13, have pronounced medicinal properties. Molecular docking revealed high affinity for binding to SARS-CoV-2 protease. Ch-p7 had the highest binding energy, likely due to its inhibitory property. A 10 ns molecular dynamics study confirmed the stability of the protein–ligand complex, resulting in minimal fluctuations in the system's backbone. The MM-GBSA analysis revealed free energies of binding of − 19.54 kcal/mol. CONCLUSIONS: The study investigated the inhibition of viral replication using chromone derivatives, finding high inhibitory effects in the peptidomimetic family compared to other studies.
format Online
Article
Text
id pubmed-10515067
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105150672023-09-23 Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study Shakibay Senobari, Zahra Masoumian Hosseini, Mohsen Teimouri, Mohammad Bagher Rezayan, Ali Hossein Samarghandian, Saeed Hekmat, Azadeh BMC Res Notes Research Note BACKGROUND: COVID-19 is a respiratory illness caused by SARS-CoV-2. Pharmaceutical companies aim to control virus spread through effective drugs. This study investigates chromone compound derivatives’ ability to inhibit viral entry and prevent replication. METHOD: This study investigated the inhibitory effect of chromone-embedded peptidomimetics and furopyrimidines on 7BZ5 from Severe Acute Respiratory Syndrome CoV-2, Homo sapiens, and 6LU7 from Bat SARS-like CoV using molecular docking. The crystal structure of these proteins was obtained from the Protein Data Bank, and the inhibition site was determined using ligand binding interaction options. The 3D structure was protonated and energetically minimised using MOE software. Chromone derivatives were designed in three dimensions, and their energy was minimised using MOE 2019. The molecular drug-likeness was calculated using SwissADME, Lipinski and Benigni-Bossa’s rule, and toxicity was calculated using Toxtree v3.1.0 software. Compounds with pharmacological properties were selected for molecular docking, and interactions were assessed using MOE 2019. MD simulations of Mpro-ch-p complexes were performed to evaluate root mean square fluctuations (RMSF) and measure protein stability. RESULT: The pharmacokinetic tests revealed that chromone derivatives of the peptidomimetic family have acceptable pharmacokinetic activity in the human body. Some compounds, such as Ch-p1, Ch-p2, Ch-p6, Ch-p7, Ch-p12, and Ch-p13, have pronounced medicinal properties. Molecular docking revealed high affinity for binding to SARS-CoV-2 protease. Ch-p7 had the highest binding energy, likely due to its inhibitory property. A 10 ns molecular dynamics study confirmed the stability of the protein–ligand complex, resulting in minimal fluctuations in the system's backbone. The MM-GBSA analysis revealed free energies of binding of − 19.54 kcal/mol. CONCLUSIONS: The study investigated the inhibition of viral replication using chromone derivatives, finding high inhibitory effects in the peptidomimetic family compared to other studies. BioMed Central 2023-09-21 /pmc/articles/PMC10515067/ /pubmed/37735703 http://dx.doi.org/10.1186/s13104-023-06508-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Note
Shakibay Senobari, Zahra
Masoumian Hosseini, Mohsen
Teimouri, Mohammad Bagher
Rezayan, Ali Hossein
Samarghandian, Saeed
Hekmat, Azadeh
Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title_full Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title_fullStr Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title_full_unstemmed Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title_short Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study
title_sort chromone-embedded peptidomimetics and furopyrimidines as highly potent sars-cov-2 infection inhibitors: docking and md simulation study
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515067/
https://www.ncbi.nlm.nih.gov/pubmed/37735703
http://dx.doi.org/10.1186/s13104-023-06508-7
work_keys_str_mv AT shakibaysenobarizahra chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy
AT masoumianhosseinimohsen chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy
AT teimourimohammadbagher chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy
AT rezayanalihossein chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy
AT samarghandiansaeed chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy
AT hekmatazadeh chromoneembeddedpeptidomimeticsandfuropyrimidinesashighlypotentsarscov2infectioninhibitorsdockingandmdsimulationstudy